Background: Because respiratory distress syndrome (RDS) affects 1% of live births, accurate and rapid assessment of markers of fetal lung maturity is critical to clinicians in deciding whether to deliver a preterm infant. Our objective was to determine the optimal diagnostic cutoff value for the TDx-FLM II assay (Abbott Laboratories) for predicting clinically significant RDS. Methods: Amniotic fluid TDx-FLM II data were collected retrospectively over 4 years. Women were included in the study if they had delivered within 72 h of TDx-FLM II testing and both the mother and infant charts could be reviewed. Women who had been treated with steroids and delivered unaffected infants were excluded from the analysis. The diagnosis of RDS was defined as infants who either were treated with surfactant and/or were placed on a ventilator and/or required continuous positive airway pressure for >1 day. Results: A total of 185 women met all entry criteria (15 RDS, 170 non-RDS). A cutoff value for a mature result of >45 mg/g gave a sensitivity of 100% (95% confidence interval, 82-100%) and a specificity of 90% (95% confidence interval, 78 -89%). Conclusions: The TDx-FLM II appears to predict clinically significant RDS when a cutoff of >45 mg/g is used
Respiratory distress syndrome (RDS) 5 is a major cause of death in the newborn. In 1998, RDS ranked fourth among leading causes of infant deaths, with 1328 deaths from RDS in the United States (1 ) . RDS, also referred to as hyaline membrane disease, is associated with insufficient surfactant production by the neonatal lung. Laboratory assessment of fetal lung maturity (FLM) before delivery enables clinicians to either delay delivery and administer steroids to hasten fetal lung development or to elect to deliver a preterm infant whose lungs are mature.
The biochemical markers for assessment of FLM are the lecithin-to-sphingomyelin ratio (L/S) and phosphatidylglycerol (PG) in amniotic fluid, determined by thinlayer chromatography (2) (3) (4) (5) (6) (7) . Chromatography, although considered the gold standard, is technically difficult and time-consuming. Alternative, more rapid assays have emerged, including foam stability, lamellar body count, PG agglutination, and fluorescence polarization. The foam stability index test is fast, easy to perform, inexpensive, and sensitive when compared with L/S and PG, but it is less specific, and there are differences in operator interpretation of results (8, 9 ) . Similarly, PG agglutination is also fast and easy to perform, but there is inconsistency in test interpretation (3, 6 ) . The lamellar body count test takes advantage of the size similarities between platelets and the lamellar bodies in the amniotic fluid and allows for counting of lamellar bodies on automated cell counters. For this reason, this assay is widely available, requires a low sample volume, and is fast, easy, and inexpensive to perform. However, there are no standardized protocols, quality-control material, or well-established cutoffs for this assay (10 -13 ) . The TDx-FLM is an automated fluorescence polarization assay that measures mg surfactant/g of albumin in amniotic fluid and reports quantitative results (14 -18 ) .
Studies evaluating the first-generation TDx-FLM I assay indicated that the Ն70 mg/g cutoff for a mature result suggested by the manufacturer was conservative and could be lowered without compromising clinical sensitivity (14, 15, 19, 20 ) . The TDx-FLM II is a second-generation fluorescence polarization assay in which the manufacturer's cutoffs have been set as follows: mature Ն55 mg/g, intermediate 40 -54 mg/g, and immature Յ39 mg/g. Preliminary studies examining the TDx-FLM II assay have indicated that the manufacturer's cutoff for this assay may also be set conservatively (21) (22) (23) . For this reason, we initiated a collaborative evaluation of the TDx-FLM II assay to determine a cutoff that would not miss prediction of clinically significant RDS. This is the largest study of its kind to date.
Materials and Methods
This study was a collaborative, retrospective cohort study in which a consecutive series of physician-ordered TDx-FLM II (Abbott Laboratories) samples, collected during a 4-year period, were examined. Data were collected from the charts of patients who had TDx-FLM II analysis performed at either Barnes-Jewish Hospital (St. Louis, MO) during 1998 -2000 or Hennepin County Medical Center (Minneapolis, MN) during 1998. During this time, 1104 physician-ordered FLM tests were performed on 881 different patients. FLM testing was ordered on women presenting with signs and symptoms of preterm labor as well as asymptomatic women before scheduled cesarean sections.
Inclusion in the study required that delivery occurred within 72 h of amniocentesis and that charts for both mother and infant were reviewable (see below). Women who received steroids before delivery and delivered non-RDS infants were excluded from the study because it is impossible to determine whether the steroids impacted the respiratory status of the infant. Women who received steroids before delivery and delivered RDS infants were included in the study because it is clear that the steroids did not impact the presence of RDS. Indeed, steroids may have changed the severity of RDS, but data were analyzed only for the presence or absence of RDS.
Barnes-Jewish Hospital performs FLM testing for a total of 12 hospitals, so we were unable to obtain charts for many of the 881 patients. Charts were available on both the mother and infant for 281 (32%) patients. Nineteen of these patients delivered Ͼ72 h from the time of FLM sampling, giving a total of 262 patients. Of these, 77 were treated with steroids and delivered non-RDS infants. Therefore, 185 patients met the inclusion criteria. Institutional Review Board approval was obtained for these studies at both institutions.
Infants who were treated with surfactant and/or were placed on a ventilator and/or required continuous positive airway pressure (CPAP) for Ͼ24 h with no other congenital anomalies were given a diagnosis of clinically significant RDS. Indications for administering surfactant include prematurity, radiologic signs of hyaline membrane disease, and mechanical ventilation or CPAP.
Six sets of twins were included in the study (three RDS, three unaffected). In all six cases only one amniotic fluid sample was obtained. However, in all six cases both twins had the same clinical outcome. Therefore, the data were included in the study although each set of twins was counted only as a single data point.
Amniotic fluid was collected by transabdominal amniocentesis or free flowing vaginal pool if the membranes were ruptured. Both types of specimens are considered acceptable for analysis by the manufacturer (24 ) . Samples with visible bilirubin, blood, or meconium were rejected. TDx-FLM II analysis was performed according to the manufacturer's instructions. The upper limit of detection was 160 mg/g, and the lower limit of detection was 10 mg/g. The L/S and the phosphatidylglycerol-to-sphingomyelin ratio (PG/S) were determined by an outside reference laboratory (Quest Diagnostics, Saint Louis, MO) by thin-layer chromatography (4, 25, 26 ) . Reference laboratory cutoffs for L/S were as follows: immature, Ͻ1.0; premature, 1.0 -1.5; intermediate, 1.5-1.9; caution mature, 2.0 -2.5; mature, Ͼ2.5. Reference laboratory cutoffs for the PG/S were as follows: immature, Ͻ0.3; mature, Ͼ0.3.
statistics
TDx-FLM II cutoff values were established with the criterion that there be no false mature results. Sensitivity refers to the probability of an immature result in a patient with RDS. Specificity refers to the probability of a mature result in a patient without RDS. Confidence intervals (CIs) for sensitivity and specificity were computed as exact binomial 95% CIs, using Stata statistical software, release 7.0 (Stata Corp.).
Results
A total of 185 women met all the inclusion criteria, of whom 170 delivered unaffected infants and 15 delivered infants with RDS. The gestational ages at time of delivery ranged from 31 to 40 1/7 weeks (median, 37 weeks) for unaffected infants and 28 to 38 6/7 weeks (median, 33 4/7 weeks) for RDS infants. The frequency of all the TDx-FLM II results based on RDS diagnosis is shown in Fig. 1 . The data demonstrate that none of the women who delivered infants with RDS had amniotic TDx-FLM II values Ն45 mg/g. Women who delivered unaffected infants and had not been treated with steroids had FLM II results ranging from 14.6 to Ͼ160 mg/g.
As shown in Table 1 (Fig. 2 ). These data demonstrate fair correlation between the two tests (r ϭ 0.73), although as shown in Table 1 , three RDS patients tested falsely mature by L/S but correctly immature by the TDx-FLM II.
Listed in Table 2 are the sensitivity (95% CI), specificity (95% CI), predictive value of a mature result, and predictive value of an immature result for cutoff values ranging from the current cutoff of Ն55 mg/g down to Ն40 mg/g. As shown in the ROC curve (Fig. 3) , lowering the mature cutoff value from Ն55 mg/g to Ն45 mg/g improved specificity, from 72% to 84%, without compromising the sensitivity of 100%. Sensitivity decreased to 93.3% when the cutoff was lowered to Ն40 mg/g. In addition, this change in cutoff increased the predictive value of an immature result from 24% to 36% (Table 2) .
Discussion
In the assessment of women who are at risk for preterm delivery, the laboratory plays an important role in predicting FLM. Following the development of the automated TDx-FLM method, we eliminated routine perfor- mance of the time-consuming and technically difficult thin-layer chromatography method for the L/S and PG/S. The manufacturer's recommended cutoff value for prediction of FLM by the TDx-FLM I was originally set at Ն70 mg/g. Studies suggested that this cutoff could be safely lowered to Ն55 mg/g, thereby increasing specificity without compromising sensitivity (14, 15, 19, 20 ) . Preliminary studies of the second-generation TDx-FLM II assay, presented as abstracts, suggested that the manufacturer's cutoff for this assay could also be lowered to between 40 and 44 mg/g (21) (22) (23) . We conducted a retrospective cohort study of TDx-FLM II results with 4 years of data to evaluate the ability of this assay to detect clinically significant RDS at different cutoff values. New TDx-FLM II cutoff values were determined, with the criterion that there be no false mature results (i.e., 100% predictive value of a positive result). Our results demonstrate that the current manufacturer's recommended cutoff for the TDx-FLM II assay can be lowered from Ն55 to Ն45 mg/g. This change does not compromise sensitivity or predictive value of a positive result and at the same time improves specificity and predictive value of an immature result. This cutoff is slightly conservative: according to the ROC curve, the cutoff could be set as low as 41 mg/g without affecting predictive values and results.
In 55 cases, a L/S was obtained concomitantly with the TDx-FLM II value. The overall correlation between L/S and TDx-FLM II values was fair (r ϭ 0.73). However, in three women who delivered infants with RDS, the L/S was in the caution mature or mature range, and in one of these cases, the PG/S was also mature. In these cases, the TDx-FLM II was clearly a better indicator of FLM than either the L/S or the PG/S.
To obtain Food and Drug Administration approval for the TDx-FLM II assay, Abbott Laboratories conducted a study with 306 patients (292 non-RDS and 14 RDS) with the highest FLM II value for an RDS patient equal to 40.33 mg/g. Using a cutoff of Ն55 mg/g, they obtained a sensitivity of 100%, specificity of 75%, a predictive value of maturity of 100%, and a predictive value of immaturity of 16% (data obtained through the Freedom of Information Act from the Department of Health and Human Services, Food and Drug Administration). If the revised cutoff of Ն45 mg/g is applied to their data, the sensitivity and predictive value of a mature result remain 100%, the specificity increases to 90%, and predictive value of an immature result increases to 33%. These data support our premise that the diagnostic cutoff can be lowered to Ն45 mg/g.
Although the largest study of its kind to date, it should be noted that our data are based on a relatively small population and that caution should be used in altering the cutoff based on a single study. For this reason, further studies are indicated to confirm our results in a population with a sufficiently broad spectrum of disease. Nevertheless, in our population, no case of clinically significant RDS had a TDx-FLM II result Ͼ40.7 mg/g. 
